Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Larimar Therapeutics, Inc. (LRMR) had Free Cash Flow of $-45.99M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-26.18M |
|
-- |
|
-- |
|
$27.79M |
|
$-27.79M |
|
$1.61M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-27.79M |
|
$-28.17M |
|
64.03M |
|
64.03M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$145.56M |
|
$0.80M |
|
$4.43M |
|
$149.99M |
|
$26.65M |
|
-- |
|
$3.48M |
|
$30.13M |
|
$119.85M |
|
$119.85M |
|
$119.85M |
|
64.03M |
|
| Cash Flow Statement Financials | |
$-45.92M |
|
$33.29M |
|
-- |
|
$33.82M |
|
$21.19M |
|
$-12.63M |
|
$3.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-45.99M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.84% |
|
-21.84% |
|
-17.46% |
|
-21.84% |
|
$1.87 |
|
$-0.72 |
|
$-0.72 |
|